Case Studies
Strategic Transactions & Partnerships in Healthcare Technology
We support clients across pharma, diagnostics, medical devices, and healthcare services — guiding high-impact deals from strategy to execution.
Positioning
DTX Pharma
The company’s siRNA delivery platform lacked a distinct identity, making it hard to stand out in a crowded biotech space.
To stand out in the crowded biotech space, Onne led a strategic rebrand, launching FALCON (Fatty Acid Ligand Conjugated OligoNucleotides) and rolling it out across all communications. He also identified and approached multiple potential partners, held multiple conversations and managed parallel due diligence processes and negotiations
The unified brand energized internal teams, sharpened external messaging, and elevated the platform’s visibility and perceived value. DTx Pharma received a key investment from Eli Lilly, identified an siRNA for a rare disease which became a lynchpin of the platform and completed Series A. Later DTx Pharma received a $100M Series B from RA Capital and was acquired in 2023 by Novartis for $1B.
Link to Media Coverage:
Cadence
Blackrock Neurotech
Blackrock needed to expand software capabilities and had early discussions in motion, but lacked bandwidth to manage the full process.
OGAdvisors led outreach and negotiations, built a target list, ran parallel discussions, interfaced with attorneys and target executives and developed valuation and board materials.
Secured the acquisition of MindX, saving the executive team time and delivering an optimized, aligned process.
Link to Media Coverage:
Team Sheet
Aegir Bio
Abreos Biosciences was preparing a joint venture with LifeAssays to commercialize a biologic toxicity assay and needed structure to move forward.
OGAdvisors developed a one-year ops plan, five-year strategy, and valuation models to support capital raising and board alignment.
The JV secured bridge financing and positioned itself for a future listing on the Stockholm Stock Exchange.
Link to Media Coverage: